# Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

> **NCT03283046** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- Multiple Myeloma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03283046
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-10
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Similar to another study.
- **Last updated:** 2017-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283046, "Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03283046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*